Gold prices edge up amid Fed rate cut hopes; US-Russia talks awaited
Steven J. Orlando, a director at Molina Healthcare Inc . (NYSE:MOH), recently sold 1,000 shares of the company’s common stock. The shares were sold at an average price of $301.33, generating a total transaction value of $301,330. The healthcare provider, with a market capitalization of $16.8 billion, maintains a "GREAT" financial health score according to InvestingPro analysis, while management has been actively buying back shares. Following this sale, Orlando holds 17,375 shares indirectly through the Orlando Family Trust and 1,500 shares in a 401(k) plan.
The transaction took place on March 3, 2025, as reported in a filing with the Securities and Exchange Commission. The shares were sold within a price range of $301.31 to $301.51.
In other recent news, Molina Healthcare reported its fourth-quarter 2024 earnings, revealing an adjusted earnings per share (EPS) of $5.05, which fell short of the expected $5.77. Despite the earnings miss, the company exceeded revenue forecasts, generating $10.5 billion against an anticipated $10.32 billion. For the full year, Molina Healthcare achieved an adjusted EPS of $22.65, marking an 8.5% increase from the previous year, and a 19% year-over-year increase in premium revenue, totaling $38.6 billion. Additionally, Molina Healthcare acquired ConnectiCare, which is projected to contribute $1.2 billion in revenue for 2025. Cantor Fitzgerald maintained its Overweight rating on Molina Healthcare, with a price target of $356.00, emphasizing the company’s significant exposure to Medicaid expansion. The firm highlighted Molina’s presence in states with trigger laws that could impact Medicaid expansion, potentially affecting the company’s financial performance. Looking ahead, Molina Healthcare projects a premium revenue of $42 billion for 2025, indicating 9% growth, and anticipates an adjusted EPS of $24.50, reflecting at least an 8% year-over-year increase.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.